[Phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Group].

Abstract

590-S is a new masked compound of 5-fluorouracil, the antimetabolic antitumor agent of the fluorinated pyrimidine group. The safe dose for the phase II study was determined during the phase I study to be 600 mg/m2/day, equivalent to 900 mg/body/day. The phase II study involving 24 institutions was performed for the treatment of gastro-intestinal cancer. A daily dose of 900 mg was given 3 times a day after meals for more than 4 weeks. The number of registered cases was 32 with stomach cancer, 17 with colo-rectal cancer and 8 with others. 4 of the 23 completed cases with stomach cancer were judged as PR, and the response rate was 19.0%. No response was found in the cases with colo-rectal cancer. Slight side effects were observed in 14 of the 44 evaluable cases. Most of these were gastro-intestinal disorders.

• Authors: T Nakatsu, H Takahashi, H Furue
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 14 Issue 11 Pg. 3114-8 (Nov 1987) ISSN: 0385-0684 [Print] Japan
• PMID: 3674897 (Publication Type: English Abstract, Journal Article)

Chemical References

• 1-phthalidyl-5-fluorouracil
• Fluorouracil

Topics

• Administration, Oral
• Adult
• Aged
• Colonic Neoplasms (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Fluorouracil (administration & dosage, analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged
• Stomach Neoplasms (drug therapy)